Study examines canine plasma xenotransfusion in 14 cats
Bottom line
A new multicenter retrospective study in the Journal of Veterinary Emergency and Critical Care reviewed 14 cats that received canine plasma xenotransfusions between 2022 and 2024, adding early evidence for a practice sometimes used when feline plasma is not available. According to the study abstract, the cases were evaluated for indications, protocols, transfusion reactions, and outcomes, and the authors concluded that canine plasma may be a life-saving option for feline coagulopathies and colloidal support, while emphasizing that its safety profile still needs further investigation. The paper appeared in Wiley’s journal feed in late April 2026. (vetlit.org)
Why it matters: For emergency and critical care teams, the report speaks to a familiar real-world problem: feline plasma can be hard to source quickly, especially after hours or in smaller hospitals. Prior literature has focused much more on canine-to-feline red cell xenotransfusion, where short-term benefit is possible but delayed hemolysis and serious reactions limit repeat use. By contrast, published evidence on canine plasma products in cats has been sparse, making this 14-case series a notable addition for clinicians weighing rescue options in coagulopathic or critically ill cats when species-matched products are unavailable. Reviews and related reports also underscore the broader transfusion-medicine context: cats often face blood-product access constraints, and other canine-derived products, including serum albumin and lyophilized platelets, have been explored in small feline case series and reports. (pmc.ncbi.nlm.nih.gov)
What to watch: Watch for the full paper, any conference discussion or commentary from transfusion specialists, and whether larger prospective studies help define when canine plasma is acceptable, how to monitor reactions, and which cats are the best candidates. (vetlit.org)
A newly listed study in the Journal of Veterinary Emergency and Critical Care examines 14 feline cases of canine plasma xenotransfusion across multiple centers from 2022 to 2024, offering one of the first focused looks at this specific practice. From the abstract, the authors assessed indications, transfusion protocols, reactions, and outcomes, and concluded that canine plasma xenotransfusion can serve as a life-saving option for feline coagulopathies and colloidal support when feline plasma is unavailable, though more work is needed to clarify safety. The article was posted in the journal’s recent-articles feed on April 30, 2026. (vetlit.org)
That matters because xenotransfusion in cats is not new, but the evidence base has centered mostly on canine red blood cells or whole blood, not plasma. Earlier reviews describe canine-to-feline xenotransfusion as an emergency workaround when compatible feline blood cannot be obtained. Those reports suggest cats generally do not have naturally occurring antibodies against canine red blood cells before a first transfusion, but they can develop antibodies rapidly afterward, with delayed hemolytic reactions often emerging within days and repeat canine red cell transfusion becoming high risk. (pmc.ncbi.nlm.nih.gov)
More recent feline studies have reinforced both the utility and the limits of xenotransfusion. A 49-case review found canine blood xenotransfusion could stabilize cats initially, but delayed hemolytic reactions were common. A later retrospective comparison of canine xenotransfusion versus type-matched feline allotransfusion added to the evidence that clinicians still turn to xenotransfusion under practical constraints, including limited access to feline products and, in some settings, cost considerations. (pubmed.ncbi.nlm.nih.gov)
Against that backdrop, the new plasma-focused report fills an important gap. The abstract indicates the 14 cats were treated for coagulopathies and for colloidal support, which suggests the product was being used not simply as a substitute transfusion, but for distinct hemostatic and oncotic goals. That lines up with adjacent literature showing how clinicians have been experimenting with other canine-derived products in cats when feline-specific options are lacking. In 2025, for example, a small retrospective Frontiers case series described canine serum albumin use in five critically ill cats and suggested it may provide oncotic and hemodynamic support, while still documenting possible transfusion-related complications, including one case attributed to circulatory overload. A separate case report described canine lyophilized platelets being used for hemostasis in a cat with postoperative hemorrhage. (frontiersin.org)
Direct outside commentary on this new paper was limited in the sources I could verify, but the broader expert literature has been consistent on the core message: xenotransfusion can be justified as a rescue strategy, not a routine substitute for feline products. Review articles and transfusion guidance emphasize that species-matched feline blood products remain the standard when available, while canine-derived products are considered because feline donors and feline blood banks remain harder to access in urgent settings. Merck’s veterinary reference also reflects the broader transfusion-medicine reality that blood typing, donor screening, and product selection remain central to safety in both dogs and cats. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this study is useful less as a practice-changing mandate than as decision support for difficult cases. Emergency hospitals, specialty centers, and overnight teams may occasionally face a cat with coagulopathy or a need for plasma-based colloidal support when feline plasma is simply not on hand. In that setting, even retrospective multicenter data can help frame risk-benefit discussions, monitoring plans, and informed consent with the pet parent. The study also highlights a larger operational issue in companion animal medicine: feline transfusion support still lags behind canine infrastructure in many markets, pushing clinicians toward improvised but potentially life-saving alternatives. (vetlit.org)
The unanswered questions are just as important. The abstract does not, at least from the publicly available summary, resolve which protocols were safest, how often reactions occurred, whether certain indications carried better outcomes, or how product choice and dosing varied by center. Those details will matter if hospitals are going to translate the findings into protocols. Prospective studies, standardized reaction reporting, and more published guidance from transfusion specialists would all help determine whether canine plasma xenotransfusion should remain a rare contingency tool or become a more formal part of feline critical care planning. (vetlit.org)
What to watch: The next step is the full paper itself, followed by conference discussion, specialist commentary, and any larger prospective work that clarifies candidate selection, dosing, monitoring, and short-term versus delayed adverse events. (vetlit.org)